Negative fFN, Who is Still Managed Aggressively and Does it Help?

Article

SMFM 27th Annual Meeting 2007

view the interview video: Negative fFN, Who is Still Managed Aggressively and Does it Help?

Abstract

Objective: Elevated levels of fetal fibronectin (fFN) in cervicovaginal secretions beyond 22 weeks gestation are used as a predictor of preterm birth in patients suspected of being in preterm labor. Previous studies have documented a negative predictive value of 97-99.5% of delivering within 7 days of testing. Providers sometimes disregard a negative result and manage the patient aggresively. Our objective was to identify which patients with a negative fFN were being managed aggressively, and if outcomes were improved with such management.

Study Design: Charts were reviewed from 121 patients evaluated in our obstetrical triage unit for "rule-out preterm labor" with negative fFN results over a 2 year period. Patients with singleton pregnancies seen between 22 and 33 6/7 weeks were included. Patient characteristics, management, and outcomes were recorded.

Results: 80 patients were managed expectantly, 41 were managed aggressively (18 were admitted, 29 were given tocolytics, 15 received steroids, 8 received antibiotics). The group managed aggressively were more likely to be dilated 1cm or more (27% vs. 3%, p<.001), or contracting at least every 8 minutes (68% vs. 23%, p<.001). Parity, prior preterm births, age and gestational age at testing were similar between the groups. None of the patients delivered within 7 or 14 days of fFN testing. The rates of preterm birth <37 weeks, <35 weeks and <32 weeks, and fFN to delivery interval were similar between the 2 groups. There was no advantage seen to aggressive management even when analyzing only the "high risk" patients (dilated 2cm, effaced >80%, contracting at least every 4 minutes, or prior preterm birth).

Conclusion: Patients with risk factors for preterm birth are more likely to be aggressively managed in the face of a negative FFN. This aggressive management does not improve outcomes.

Download Dr. Pelaez's poster in PDF format here

0002-9378/$ - see front matter
doi:10.1016/j.ajog.2006.10.853
American Journal of Obstetrics and Gynecology
Volume 195, Issue 6, Supplement S (December 2006)

Recent Videos
Laurence Shields, MD, is System Physician Vice President at the Women and Infants Clinical Institute with CommonSpirit Health in Santa Maria, California.
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Henri M. Rosenberg, MD
Study explores the limits of neighborhood data in predicting preterm birth | Image Credit: linkedin.com
Barbed suture reduces blood loss in hysterectomy | Image Credit: linkedin.com
Integrase inhibitors not linked to neonatal weight | Image Credit: linkedin.com
How AI is revolutionizing prenatal detection of congenital heart defects | Image Credit: mfmnyc.com/team.
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Related Content
© 2025 MJH Life Sciences

All rights reserved.